<aside> 💡 Cyfuse Biomedical (founded in 2010, headquartered in Tokyo) is garnering significant attention in the field of regenerative medicine. The company's core activities appear to center on the innovative development and ongoing efforts toward the commercialization of 3D cell products. By harnessing the power of three-dimensional cell culture, they are undoubtedly aiming to unlock new possibilities in medical treatments.
Their vision is to deliver "new 'hope'" to patients worldwide through the power of "cells." This ambition is supported by their proprietary "Regenova" and "S-PIKE" bio 3D printers, developed in-house. These technologies represent a crucial strength, positioning Cyfuse at the forefront of creating intricate 3D cellular structures.
A particularly noteworthy recent development is the company's clear movement towards market entry. The announcement in March 2025 of a partnership with PHC to develop new production technology specifically for the commercialization of their 3D cell products strongly indicates a serious and explicit intention to translate their scientific advancements into tangible medical solutions. This collaborative research and development is likely to be a significant indicator of the marketability and potential real-world impact of their innovative products.
While specific details regarding their technology and products remain undisclosed, information available on their website suggests a deep commitment to the future of regenerative medicine and a clear objective of delivering their unique 3D cell technologies to patients. We look forward to observing their future endeavors. (AS)
Return to English Top
</aside>
A 3D bioprinter that can create transplantable organs from patients' own cells
Cellular 3D Printer Brings New Hope / The Government of Japan - JapanGov -